These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 912512

  • 1. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ, Catto GR, Macleod M.
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A, Bordier P, Gueris J, Sebert JL, Marie P, Ferrière C, Bedrossian J, DeLuca HF.
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract] [Full Text] [Related]

  • 3. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
    Pierides AM, Ellis HA, Ward MK, Simpson W, Kerr DN.
    Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ, Bone JM, Anderson TJ, Robson JS.
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
    Offermann G, Schaefer K, Schulz A, Delling G.
    Klin Wochenschr; 1976 Jul 01; 54(13):625-32. PubMed ID: 940299
    [Abstract] [Full Text] [Related]

  • 12. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
    Sebert JL, Marie A, Kuntz D, Marie P, Gueris J, Smadja A, Fournier A, Quichaud J.
    Rev Rhum Mal Osteoartic; 1981 Jul 01; 48(7-9):535-41. PubMed ID: 7291931
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL, Brownjohn AM, Goodwin FJ, Hately W, Manning RM, O'Riordan JH, Papapoulos SE, Marsh FP.
    Q J Med; 1982 Jul 01; 51(203):271-8. PubMed ID: 7146311
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Histological, hormonal, biochemical and radiological evaluation of vit. D therapy in osteodystrophy patients on RDT.
    Brancaccio D, Graziani G, Faccini JM, Banfi G, Pedoja G, Watson L.
    J Urol Nephrol (Paris); 1976 Jul 01; 82(4-5):359-62. PubMed ID: 940182
    [No Abstract] [Full Text] [Related]

  • 20. Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.
    Chesney RW, Hamstra A, Jax DK, Mazess RB, DeLuca HF.
    Contrib Nephrol; 1980 Jul 01; 18():55-71. PubMed ID: 7353380
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.